Mode
Text Size
Log in / Sign up

Persistent microvascular obstruction predicts higher MACE and death risks following ST-segment elevation myocardial infarctionPersistent heart muscle damage after heart attack increases risk

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that persistent microvascular obstruction is associated with higher MACE and death risk following STEMI.

This meta-analysis evaluates the prognostic significance of persistent microvascular obstruction (MVO) in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention and cardiac magnetic resonance imaging. The analysis included 2180 patients to compare outcomes between those with persistent MVO and those with transient MVO or no MVO.

Findings indicate that persistent MVO is associated with higher risks of MACE and death compared to transient MVO. Furthermore, patients with persistent MVO exhibited lower LVEF and larger infarct size than those with transient MVO. While persistent MVO showed stronger associations with adverse outcomes like heart failure readmission and lower LVEF when compared to no-MVO, no significant association was found between persistent MVO and recurrent MI or heart failure readmission when compared specifically to transient MVO.

The authors note significant clinical heterogeneity due to varying definitions and timing of persistent MVO, which ranged from 1 week to 12 months across studies. Follow-up duration was not reported. These findings suggest that follow-up CMR may be useful for risk stratification to identify high-risk populations in the post-STEMI period.

How this fits prior evidence

This meta-analysis addresses a gap in identifying specific imaging biomarkers for risk stratification following STEMI. It complements existing evidence regarding infarct size, as it identifies persistent MVO as a factor associated with larger infarct size compared to transient MVO. While previous coverage noted that transvalvular microaxial flow pump plus PCI does not reduce infarct size in anterior STEMI, this meta-analysis highlights the prognostic value of identifying patients with large infarct sizes and lower LVEF via CMR.

When someone suffers a heart attack, the tiny blood vessels in their heart can become damaged. This is called microvascular obstruction (MVO). Doctors use special imaging to see if this damage stays for a long time or clears up quickly. This study looked at 2,180 patients who had an emergency procedure to open blocked arteries.

The researchers found that persistent MVO—damage that stays after the initial heart attack—is linked to worse outcomes. Specifically, patients with lasting damage showed higher risks of death and major medical events compared to those whose damage was only temporary. These patients also had lower heart muscle function and larger areas of damaged tissue.

While some issues like repeat heart attacks or hospital readmissions for heart failure did not show a clear link to the type of MVO, the overall risk remains higher when damage is persistent. Because different studies used different ways to measure this timing, the results are based on varied data points. Doctors may use these imaging tests to better identify which patients need more intensive care.

What this means for you:
Persistent damage to tiny heart vessels after a heart attack is linked to higher death risks and worse heart function.

Common questions

What is microvascular obstruction?

Microvascular obstruction (MVO) refers to damage or blockage in the tiny blood vessels of the heart. When this damage is persistent, it means the tissue remains damaged after a heart attack. The study found that patients with persistent MVO had lower heart muscle function and larger areas of damaged tissue compared to those with only temporary damage.

How does lasting vessel damage affect recovery?

Patients with persistent MVO showed higher risks of death and major medical events (MACE) than those with transient, or temporary, damage. While the study did not find a significant link between persistent MVO and repeat heart attacks or hospital readmissions for heart failure, the overall risk profile is worse for patients with lasting damage.

How do doctors use this information?

Doctors can use cardiac magnetic resonance (CMR) imaging to check for microvascular obstruction. This helps them identify high-risk patients who may need more careful monitoring after a heart attack. Because the study involved 2,180 patients, it provides a broad look at how these findings might help with risk stratification.

Study Details

Study typeMeta analysis
Sample sizen = 2,180
EvidenceLevel 1
PublishedAug 2026
View Original Abstract ↓
BACKGROUND: Microvascular obstruction (MVO) frequently occurs after primary percutaneous coronary intervention (PCI) in patients with ST-segment elevation myocardial infarction (STEMI) and can be classified as transient or persistent based on its resolution on follow-up cardiac magnetic resonance (CMR) imaging. This meta-analysis aims to compare the prognostic significance of persistent MVO versus transient MVO and no MVO in patients with STEMI undergoing primary PCI. METHODS: we conducted a systematic search for cohort studies comparing persistent MVO to transient MVO or no MVO in patients with STEMI who underwent primary PCI and CMR imaging. For the meta-analysis, we used R software (version 4.5.0) with RStudio. RESULTS: We included seven cohort studies with a total of 2180 patients. Compared to transient MVO, persistent MVO was associated with significantly higher risks of MACE and death. Persistent MVO also demonstrated significantly lower LVEF and larger infarct size, but no significant association with recurrent MI or heart failure readmission. Compared to no-MVO, persistent MVO showed even stronger associations with adverse outcomes: MACE, death, heart failure readmission, lower LVEF, and larger infarct size. CONCLUSION: Persistent MVO may be associated with worse clinical outcomes, adverse left ventricular remodeling, and larger infarct size compared to both transient MVO and no MVO. These findings support the role of follow-up CMR for risk stratification to identify high-risk population. However, the definition and timing of persistent MVO varied considerably across studies (1 week to 12 months), which introduce clinical heterogeneity highlighting the need for future studies with standardized definitions.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.